Get started
Author

Stéphanie Cornen

Harnessing innate immunity in cancer therapy
2019 · Olivier Demaria, Stéphanie Cornen, et al. · Nature · 971
Natural killer cell therapies
2024 · Eric Vivier, Lucas Rebuffet, et al. · Nature · 496
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
2019 · Laurent Gauthier, Ariane Morel, et al. · Cell · 451
PDF
Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant
2022 · Olivier Demaria, Laurent Gauthier, et al. · Cell Reports Medicine · 78
PDF
Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling
2014 · Stéphanie Cornen, Arnaud Guille, et al. · PLoS ONE · 72
Chemotherapy and tumor immunity
2018 · Stéphanie Cornen, Eric Vivier · Science · 66
Mutations and deletions of ARID1A in breast tumors
2012 · S Cornen, J Adelaide, et al. · Oncogene · 57
Publisher Correction: Harnessing innate immunity in cancer therapy
2019 · Olivier Demaria, Stéphanie Cornen, et al. · Nature · 21
PDF
123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
2021 · D.A. Colevas, K. Misiukiewicz, et al. · Annals of Oncology · 12
PDF
Abstract 2713: Preclinical development of first-in-class antibodies targeting Siglec-9 immune checkpoint for cancer immunotherapy
2018 · Olivier Bénac, Marion Gaudin, et al. · Cancer Research · 11
Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control
2021 · Mathieu Bléry, Manel Mrabet-Kraiem, et al. · Open Research Europe · 8
851 Harnessing innate immunity in cancer therapies: the example of natural killer cell engagers
2021 · Olivier Demaria, Eric Vivier, et al. · Journal for ImmunoTherapy of Cancer · 5
PDF
Targeting MICA with therapeutic antibodies for the treatment of cancer
2013 · Cécile Bonnafous, Valentine Peri, et al. · Journal for ImmunoTherapy of Cancer · 5
PDF
81P Monalizumab in combination with cetuximab post platinum and anti-PD-(L)1 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from a phase II trial
2020 · J. Fayette, J. Bauman, et al. · Annals of Oncology · 4
Les cellules natural killer : des cibles prometteuses dans la thérapie contre le cancer
2019 · Stéphanie Cornen, Pascale André, et al. · médecine/sciences · 2
PDF
Abstract 5037: Targeting MICA with therapeutic antibodies for the treatment of cancer
2014 · Mathieu Blery, Cécile Bonnafous, et al. · Cancer Research · 2
Integrated Genomic Analysis of Breast Cancers
2012 · Max Chaffanet, L Addou-Klouche, et al. · Balkan Journal of Medical Genetics · 2
PDF
10th antibody industrial symposium: new developments in antibody and adoptive cell therapies
2023 · Ana Antunes, Luis Alvarez-Vallina, et al. · mAbs
PDF
1O Harnessing innate immunity in cancer therapies: The example of natural killer cell engagers
2021 · E. Vivier, M. Vetizou, et al. · Annals of Oncology
Caractérisation moléculaire des cancers du sein luminaux B
2013 · Stéphanie Cornen · theses.fr (ABES)
Works count: 20
Citation count: 2,263
H-index: 10
I10-index: 10
Year
Topic
Type